, Volume 115, Issue 2, pp 221-222
Date: 18 May 2009

Cost-effective analyses in Breast Cancer Research and Treatment

This is an excerpt from the content

Since its inception, Breast Cancer Research and Treatment (BCRT) has been a publication source for manuscripts that describe new laboratory, clinical, or epidemiologic data regarding breast cancer. In addition, the Editors have encouraged thoughtful state-of-the-art reviews and commentaries. During this time, the field has witnessed remarkable progress in our understanding of the genetics and molecular biology that drive the breast cancer phenotype and in the evaluation and treatment of patients with this disease. Indeed, these successes have led to a plethora of new diagnostic and treatment strategies that have been accompanied by a dramatic decline in breast cancer mortality in the Western world over the last 30 years [1, 2].

However, these new advances are not without cost. Concomitant with progress has come a concern over the financial implications of supplying these new treatments to patients. This concern has led to an entirely new field of research: analysis of cost effectiveness ...

An erratum to this article can be found at http://dx.doi.org/10.1007/s10549-010-0743-0